What changed from existing technology?
This study tested different calcium hydroxylapatite fillers to see how they affect skin cells under aging conditions.
The study is the first to compare how different CaHA formulations affect gene expression in aging-like fibroblasts.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
cts on fibroblast biology under aging-like conditions remain incompletely characterized. This study aimed to compare the gene-expression responses induce
Abstract ↗OpenAlex author affiliations: Microsoft (Brazil), Instituto Vital Brazil (Brazil)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings may help in developing more effective dermal fillers for skin rejuvenation.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchDifferential Modulation of Extracellular Matrix- and Longevity-Related Gene Expression by Calcium Hydroxylapatite FormulationsLife · Published 2026-08-25 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.